These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 18950981)

  • 1. Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
    Clunie GP; Clark A; Mortimer CJ; Stephenson S; Aitken J; Smith C; Sherwin E; Archer TJ
    Eur J Surg Oncol; 2009 May; 35(5):475-80. PubMed ID: 18950981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging bone health issues in women with breast cancer in Hawai'i.
    Carney JF; Davis J
    Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
    Rozenberg S; Carly B; Liebens F; Antoine C
    Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase inhibitors and bone health.
    Bundred NJ
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of aromatase inhibitors on bone metabolism].
    Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
    Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer.
    Ghazi M; Roux C
    Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):805-11. PubMed ID: 19945692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of osteoporosis after breast cancer.
    Reid DM
    Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of third-generation aromatase inhibitors on bone.
    McCloskey E
    Eur J Cancer; 2006 May; 42(8):1044-51. PubMed ID: 16554149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing the risk of bone loss associated with breast cancer treatment.
    Hadji P
    Breast; 2007 Dec; 16 Suppl 3():S10-5. PubMed ID: 18023583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P; Bundred N
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on identifying and managing osteoporosis in women with breast cancer.
    Yamamoto DS; Viale PH
    Clin J Oncol Nurs; 2009 Oct; 13(5):E18-29. PubMed ID: 19793700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
    Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
    J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
    Coleman RE; Body JJ; Gralow JR; Lipton A
    Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoporosis risk in premenopausal women.
    Vondracek SF; Hansen LB; McDermott MT
    Pharmacotherapy; 2009 Mar; 29(3):305-17. PubMed ID: 19249949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
    Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM; Moore TE
    Cancer Nurs; 2008; 31(3):182-90. PubMed ID: 18453874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
    Barginear M; Clotfelter A; Poznak CV
    Clin Breast Cancer; 2009 May; 9(2):72-6. PubMed ID: 19433386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.